Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Post Renal Transplantation Clear all
Recruiting Not applicable Interventional

Feasibility and Plausible Effectiveness of a Lifestyle Intervention in Kidney Transplant Recipients (HEAL)

NCT06640179
View directory record Official record
Conditions
Kidney Transplant, Overweight or Obese Adults, Glucose Control
Interventions
Standard medical care, Monitoring Contacts, Behavioral Sessions, Diet, Physical Activity
Other · Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 23, 2026, 6:31 AM EDT
Completed Phase 4 Interventional

Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation

NCT00087581
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Mycophenolate mofetil, Cyclosporine, Tacrolimus
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years to 75 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
57
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 48 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2016 · Synced Jul 23, 2026, 6:31 AM EDT
Completed Phase 1 Interventional

Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors

NCT01661400
View directory record Official record
Conditions
Glioma, Neuroectodermal Tumors, Primitive, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Retinoblastoma
Interventions
Metronomic Cyclophosphamide, Thalidomide
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Months to 21 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Jul 23, 2026, 6:31 AM EDT
Terminated Phase 3 Interventional Results available

Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function

NCT04258423
View directory record Official record
Conditions
Kidney Failure
Interventions
Tacrolimus, Everolimus
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Jul 23, 2026, 6:31 AM EDT
Completed Phase 2 Interventional Results available

Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation

NCT03961256
View directory record Official record
Conditions
Pre Diabetes
Interventions
Exenatide SR
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Jul 23, 2026, 6:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant

NCT03380377
View directory record Official record
Conditions
Antibody-mediated Rejection, Kidney Transplant; Complications, Transplant Glomerulopathy, Transplant Glomerulopathy - Late Form, Transplant Glomerulopathy - Early Form, Kidney Transplant Rejection
Interventions
Clazakizumab
Drug
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
15 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Jul 23, 2026, 6:31 AM EDT
Completed Phase 2 Interventional Results available

Belatacept Post Depletional Repopulation to Facilitate Tolerance

NCT00565773
View directory record Official record
Conditions
Organ Transplantation
Interventions
Belatacept, Sirolimus, Alemtuzumab
Drug
Lead sponsor
Allan D Kirk, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Jul 23, 2026, 6:31 AM EDT
Withdrawn Phase 1 Interventional

Pancreatic Islet Cell Transplantation After Kidney Transplantation - A Novel Approach to Immunosupression

NCT03047200
View directory record Official record
Conditions
Islet Cell Transplantation, Type 1 Diabetes
Interventions
Islet cell transplantation
Biological
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Jul 23, 2026, 6:31 AM EDT
Completed Phase 2 Interventional Results available

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

NCT04572854
View directory record Official record
Conditions
C3G, IC-MPGN, Renal Transplant, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Dense Deposit Disease (DDD), Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulonephritis
Interventions
Pegcetacoplan
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 23, 2026, 6:31 AM EDT
Completed Phase 3 Interventional

Efficacy of Islet After Kidney Transplantation

NCT00468117
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islet transplantation, Antithymocyte Globulin, Daclizumab or Basiliximab, Etanercept, Allogenic human purified pancreatic islets
Procedure · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 68 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
9
States / cities
San Francisco, California • Miami, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Jul 23, 2026, 6:31 AM EDT
Terminated Not applicable Interventional

Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation

NCT00579592
View directory record Official record
Conditions
Acute Rejection, Renal Transplantation
Interventions
Campath-1H, rituximab, myfortic
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Jul 23, 2026, 6:31 AM EDT
Not listed No phase listed Observational

Trajectories of Glomerular Filtration Rate and Progression to End Stage Renal Disease After Kidney Transplantation

NCT04226859
View directory record Official record
Conditions
Kidney Transplant Failure, Kidney Function Issue
Interventions
No intervention
Other
Lead sponsor
Paris Translational Research Center for Organ Transplantation
Other
Eligibility
18 Years and older
Enrollment
14,000 participants
Timeline
2000 – 2020
U.S. locations
5
States / cities
Los Angeles, California • Baltimore, Maryland • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Jul 23, 2026, 6:31 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Islet After Kidney Transplant for Type 1 Diabetes

NCT00784966
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
etanercept
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Jul 23, 2026, 6:31 AM EDT
Completed No phase listed Observational

Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus

NCT03413722
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Tacrolimus, Everolimus
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Jul 23, 2026, 6:31 AM EDT
Completed Phase 4 Interventional Results available

Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant

NCT01928199
View directory record Official record
Conditions
Posttransplant Diabetes Mellitus
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Jul 23, 2026, 6:31 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant

NCT03737604
View directory record Official record
Conditions
Transplant;Failure,Kidney, Pain, Postoperative
Interventions
Ropivacaine Continuous Infusion Catheter, Single Dose Liposomal Bupivicaine
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 23, 2026, 6:31 AM EDT
Completed Not applicable Interventional

Nutrient Levels Alter Transplant Outcome

NCT00560014
View directory record Official record
Conditions
Chronic Renal Disease
Interventions
Arginine and canola oil, Coromega and Arginine
Dietary Supplement
Lead sponsor
University of Cincinnati
Other
Eligibility
Not listed
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2007 · Synced Jul 23, 2026, 6:31 AM EDT
Completed No phase listed Observational

Multidimensional System to Dynamically Predict Graft Survival After Kidney Transplantation

NCT04258891
View directory record Official record
Conditions
Kidney Transplant Failure
Interventions
No intervention
Other
Lead sponsor
Paris Translational Research Center for Organ Transplantation
Other
Eligibility
18 Years and older
Enrollment
14,000 participants
Timeline
2004 – 2020
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Jul 23, 2026, 6:31 AM EDT
Not yet recruiting Phase 2 Interventional

(TNX-1500) in Kidney Transplant Recipients

NCT07204080
View directory record Official record
Conditions
Kidney Transplant, Kidney Transplant Failure and Rejection, Immunosuppression, Immunosuppression After Kidney Transplantation
Interventions
TNX-1500, Kidney Transplant
Drug · Procedure
Lead sponsor
Ayman Al Jurdi, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 23, 2026, 6:31 AM EDT
Not listed Phase 4 Interventional

Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression

NCT01875224
View directory record Official record
Conditions
New Onset Diabetes After Transplant, Kidney Transplantation
Interventions
Belatacept, Tacrolimus
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Jul 23, 2026, 6:31 AM EDT
Completed Early Phase 1 Interventional

Post-operative Complications and Graft Survival With Conventional Versus Continuous Glucose Monitoring in Patients With Diabetes Mellitus Undergoing Renal Transplantation

NCT04742023
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Continuous Glucose Monitor Application, Finger Stick Glucose Measurement, Insulin, Continuous Glucose Monitor Placebo Applied
Device · Diagnostic Test · Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced Jul 23, 2026, 6:31 AM EDT
Terminated Phase 4 Interventional Results available

Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation

NCT02974686
View directory record Official record
Conditions
Kidney Transplant Rejection, Gastrointestinal Disorder, Functional
Interventions
Everolimus, Mycophenolic Acid
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 9, 2020 · Synced Jul 23, 2026, 6:31 AM EDT
Withdrawn Not applicable Interventional

Post Kidney Transplant Nocturnal Hypertension Prevalence and Management Study

NCT01120613
View directory record Official record
Conditions
Hypertension
Interventions
Chronotherapy
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Great Neck, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Jul 23, 2026, 6:31 AM EDT
Completed Phase 2 Interventional Results available

COVID Protection After Transplant-Immunosuppression Reduction

NCT05077254
View directory record Official record
Conditions
Kidney Transplant Recipients, Liver Transplant Recipients
Interventions
Pfizer-BioNTech COVID-19 Vaccine 2023-2024, Moderna COVID-19 Vaccine 2023-2024, SOC IS Regimen, SOC IS Reduction
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 23, 2026, 6:31 AM EDT